STUDY Abstract: LBP-0231 The percentage of patients with HCV infection in need of a liver transplant is rapidly declining while their survival after transplantation is improving: a study based on European Liver Transplant Registry – G. Perricone, et al.
Study Aims and Results: The objective of the study was to understand the effect of direct-acting antiviral (DAA) treatment on the hepatitis C (HCV) liver transplants and improved outcomes post-transplant. The study reviewed 36,000 liver transplantations for hepatitis B (HBV), alcoholic liver disease (ALD) or non-alcoholic steatohepatitis (NASH). The study reviewed the European Liver Transplant Registry between January 2007 – June 2017. I am only including the second-generation period of the DAA period (2014 – June 2017).
Liver transplantations for HCV decreased by 21% during the first half of 2014 to 11% during the first half of 2017. The survival of HCV patients with HCV post-transplants improved and was comparable to post-transplant HBV patients.
NASH transplants increased from 1% to 6% and transplants due to ALD remained the same.
Conclusion: In Europe, the number of liver transplants has declined since the introduction of DAA therapy.
Editorial Comments: More good news about the widespread use and effectiveness of DAA therapy.
Share This Page